+86（1812）4514114 info@phcoker.com

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7)

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7)

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7)

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7)

Rated 5.00 out of 5 based on 1 customer rating

GM1 powder has been widely used to treat neonatal hypoxic-ischemic brain injury, Parkinson’s disease…..

Status:	In Mass Production
Synthesized and Customized Available
Capacity:	1277kg/month

SKU: 37758-47-7 Category: Smart Drug

Description
References & product citations

Description

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7) video

<span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span><span data-mce-type="bookmark" style="display: inline-block; width: 0px; overflow: hidden; line-height: 0;" class="mce_SELRES_start"></span>

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7) Description

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7), the short name can be GM1, extracted from pig’s brain and is a member of the ganglio series of gangliosides which contain one sialic acid residue.

GMl can promote the recovery of neurological function after injury of the central nervous system of a variety of causes, promote neuroplasticity. Experiments show GMl vascular brain injury, traumatic brain to restore nerve cells in spinal cord injury has a protective effect and promote the role of cell.

Previous phase II clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity(OIN). But it did not certificated by phase III trial. A phase III trial is needed to investigate the effect and safety of monosialotetrahexosylganglioside Sodium Injection for prevention OIN at gastric cancer.

Monosialotetrahexosylganglioside Sodium (GM1) pig brain (37758-47-7) Specifications

Product Name	Monosialotetrahexosylganglioside Sodium (GM1) pig brain
Chemical Name	Monosialotetrahexosylganglioside Sodium (Porcine brain) Or GM1
Sequence	/
Brand Name	Shenjie
Drug Class	Sphingolipids
CAS Number	37758-47-7
InChIKey	GTTLZSUWCRJZRC-CRQBLQEMSA-N
Molecular Formula	C73H134N4O31
Molecular Weight	1563.85
Monoisotopic Mass	1563.85
Melting Point	N/A
Biological Half-Life	/
Color	Off-white lyophilized powder
Solubility	chloroform/methanol (9:1): 10 mg/mL, clear, colorless
Storage Temperature	-20°C
Application	Specific receptors for cholera toxin that accumulate in the brain in late infantile lipidosis.
Testing items	In house Quality Standards
Character	White or white powder; slightly smelly, tasteless; wet. This product is soluble in water, very slightly dissolved in methanol, almost insoluble in anhydrous ethanol.
Identification
Color rendering reaction 1	Take the test solution 0.2ml under the content determination, add water 2ml, and then add the Hydroquinone hydrochloric acid solution (hydroquinone 0.2g, add water 10ml dissolved, add hydrochloric acid 90ml, add 0.1mol/L Copper sulfate solution 0.25ml, refrigerator Preservation) 2ml, water bath heating for 15 minutes, solution blue and purple, with N-e alcohol 5ml Vibration extraction, n-e alcohol layer is blue.
Color rendering reaction 2	Take this product about 20mg, add glacial acetic acid 1ml, hot water bath heating fully dissolved, add three ferric chloride test fluid 1 drops, in the hot water bath along the pipe wall slowly add sulfuric acid 1ml, so that the solution into two layers, the two-liquid interface should be brown
Sodium salt	The identify reaction of sodium salt in this product (Chinese Pharmacopoeia 2015 edition four 0301).
Liquid chromatography(LC)	In the chromatographic graph recorded under the content determination, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the control solution.
Infrared spectroscopy	The infrared light absorption map of this product should be consistent with the map of the control product (Chinese Pharmacopoeia 2015 edition four 0402).
Inspect
PH	5.0～6.5
Clarity and color of solution	Should be clarified colorless; if it is cloudy, it shall not be thicker than the standard liquid of turbidity No. 1th; If the color rendering should not be deeper than the Yellow No. 1th colorimetric solution.
High Pressure determination	The finished solution should be clear and transparent after high temperature, no milk light, no precipitation
Sensitizing factor (Miscellaneous protein)	≤50000
Total Sialic acid	According to the dry product calculation, the saliva containing acid should be 19.0~21.0%
Related substances	Sialic acid ≤0.3%;GD3, GD1a, unknown impurities are ≤ 0.5%; impurities and ≤2.0%
Protein	≤1.0%
High molecular weight impurities	≤0.5%
Residual solvents	Methanol ≤ 0.1%; acetone ≤ 0.3%; Trichloromethane ≤0.003%
Water	≤4.0%
Burning residue	≤5.0%
Heavy metal	≤20ppm
Abnormal toxicity	Comply Regulations
Antihypertensive substances	Should be in accordance with the regulations (multiple quantities of administration)
Pyrogen	Should be in accordance with the regulations (multiple quantities of administration)
Microbial limits	The total number of aerobic bacteria should be <100cfu/g, and the total number of molds and yeasts should be <50cfu/g
Specific	≥98.0%

Raw MONOSIALOTETRAHEXOSYLGANGLIOSIDE SODIUM (GM1) powder (37758-47-7) Description

Monosialotetrahexosylganglioside Sodium (37758-47-7), the short name can be GM1, extracted from pig’s brain and is a member of the ganglio series of gangliosides which contain one sialic acid residue.

GM1 can promote the recovery of neurological function after injury of the central nervous system of a variety of causes, promote neuroplasticity. Experiments show GM1 vascular brain injury, traumatic brain to restore nerve cells in spinal cord injury has a protective effect and promote the role of cell.

Previous phase II clinical trial showed, it can reduce oxaliplatin-induced neurotoxicity(OIN). But it did not certificated by phase III trial. A phase III trial is needed to investigate the effect and safety of monosialotetrahexosylganglioside Sodium Injection for prevention OIN at gastric cancer.

MONOSIALOTETRAHEXOSYLGANGLIOSIDE SODIUM (GM1) powder (37758-47-7) Mechanism of actions?

GM1 (monosialotetrahexosylganglioside) the “prototype” ganglioside, is a member of the ganglio series of gangliosides which contain one sialic acid residue. GM1 has important physiological properties and impacts neuronal plasticity and repair mechanisms, and the release of neurotrophins in the brain. Besides its function in the physiology of the brain, GM1 acts as the site of binding for both cholera toxin and E. coli heat-labile enterotoxin (Traveller’s diarrhea).

Benefits of MONOSIALOTETRAHEXOSYLGANGLIOSIDE SODIUM (GM1) powder (37758-47-7)

Ganglioside GM1 is a member of the ganglioside family which has been used in many countries and is thought of as a promising alternative treatment for preventing several neurological diseases, including cerebral ischemic injury. The therapeutic effects of GM1 have been proved both in neonates and in adults following ischemic brain damage.

Recommended MONOSIALOTETRAHEXOSYLGANGLIOSIDE SODIUM (GM1) powder (37758-47-7) Dosage

Drug was administered at the dose of 20-40 mg daily by intravenous or slowly intramuscular injection according to the doctor’s advices. In the acute phase of pathological changes: Drug was used at the dose of 100 mg daily by intravenous injection; After 2-3 weeks, generally maintain the amount of 20-40 mg daily for six weeks, the first dose of 500-1000 mg was administered by intravenous drip for Parkinson’s disease; since the second day, drug was used with the dose of 200 mg daily by subcutaneous, intramuscular injection or intravenous drip for 18 weeks usually. when this drug was administered by Subcutaneous or intravenous injection ,it should be dissolved and diluted in water for injection until the concentration of 10 mg / ml at the;when Intravenous drip, drug was disloved and diluted in 0.9% sodium chloride injection or 5% glucose injection .

Side effects of MONOSIALOTETRAHEXOSYLGANGLIOSIDE SODIUM (GM1) powder (37758-47-7)

The side effect of GM1 powder is mainly rash reaction after use.

References & product citations

© Shangke Chemical 2019 | Created with by www.phcoker.com

Azərbaycan dili

বাংলা

Беларуская мова

Български

ქართული

Ελληνικά

ગુજરાતી

Ōlelo Hawaiʻi

עִבְרִית

हिन्दी

Bahasa Indonesia

ಕನ್ನಡ

Қазақ тілі

ភាសាខ្មែរ

Кыргызча

ພາສາລາວ

Latviešu valoda

Lietuvių kalba

Lëtzebuergesch

Македонски јазик

മലയാളം

मराठी

ဗမာစာ

नेपाली

ਪੰਜਾਬੀ

Српски језик

සිංහල

தமிழ்

తెలుగు

Українська